The Lung Clearance Index, measured by multiple breath washout, is a measure of lung function that is considered a research tool in Canada as the device used to measure it is not approved by Health Canada. The study will assess lung function in patients undergoing routine lung function testing for clinical indications (Cystic Fibrosis and Other Respiratory Diseases). In addition, healthy controls of different ages will be asked to perform this lung function test to gain reference data that can be used to interpret LCI in patients with lung disease.
Felix Ratjen, MD PhD | |
416-813-7654 | |
[email protected] |
Sanja Stanojevic, PhD | |
416-813-7654 | |
[email protected] |
30 Months - 30 Years
Observational
All
2.5 – 18 years of age at enrolment
Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:
A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)
A documented genotype with two disease-causing mutations in the CFTR gene
Informed consent by participant, parent, or legal guardian
Ability to perform technically acceptable MBW measurements
Physical findings at screening that would compromise the safety of the participant as judged by the patient’s most responsible physician
Requirement of supplementary oxygen to maintain an oxygen saturation above 95%
Participants with other respiratory disease